We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
Cap. Flow
+$783M
Cap. Flow %
17.35%
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$94.6M
2
AZN icon
AstraZeneca
AZN
+$82.2M
3
BAX icon
Baxter International
BAX
+$68.1M
4
CRBU icon
Caribou Biosciences
CRBU
+$60.5M
5
STVN icon
Stevanato
STVN
+$59.9M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$124M
2
MDT icon
Medtronic
MDT
+$66.4M
3
BIIB icon
Biogen
BIIB
+$63.7M
4
NEO icon
NeoGenomics
NEO
+$61.7M
5
LLY icon
Eli Lilly
LLY
+$58.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.59%
2 Technology 0.99%
3 Financials 0.53%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
76
Instil Bio
TIL
$49.2M
$7.3M 0.16%
20,407
+407
+2% +$152K
GLUE icon
77
Monte Rosa Therapeutics
GLUE
$1.84B
$6.68M 0.15%
300,000
– –
ONCS
78
DELISTED
OncoSec Medical Incorporated
ONCS
$6.27M 0.14%
133,864
+6,591
+5% +$334K
TRML
79
DELISTED
Tourmaline Bio
TRML
$6.17M 0.14%
45,500
+1,864
+4% +$255K
XLRN
80
DELISTED
Acceleron Pharma
XLRN
$6.02M 0.13%
35,000
-323,500
-90% -$42.3M
KROS icon
81
Keros Therapeutics
KROS
$198M
$5.74M 0.13%
+145,100
New +$5.16M
TCRT icon
82
Alaunos Therapeutics
TCRT
$4.62M
$5.46M 0.12%
+20,000
New +$6.12M
MSAC
83
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.07M 0.11%
520,000
– –
ARYD
84
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$5.03M 0.11%
500,000
– –
BLSA
85
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.98M 0.11%
500,000
– –
SNTI icon
86
Senti Biosciences Holdings
SNTI
$11M
$4.97M 0.11%
50,000
– –
HCAQ
87
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$4.95M 0.11%
500,000
– –
PANA
88
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.11%
500,000
– –
SLGC
89
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.09M 0.09%
+330,000
New +$3.72M
OBIO icon
90
Orchestra BioMed
OBIO
$234M
$3.96M 0.09%
400,000
– –
MLTX icon
91
MoonLake Immunotherapeutics
MLTX
$1.58B
$3.94M 0.09%
400,000
– –
SNCE
92
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3.92M 0.09%
20,000
– –
TNGX icon
93
Tango Therapeutics
TNGX
$4.25B
$3.88M 0.09%
300,000
– –
ZLAB icon
94
Zai Lab
ZLAB
$2.06B
$3.75M 0.08%
35,600
-64,400
-64% -$9.25M
NAUT icon
95
Nautilus Biotechnolgy
NAUT
$147M
$3.68M 0.08%
600,000
-525,000
-47% -$4.18M
SGHT icon
96
Sight Sciences
SGHT
$290M
$3.3M 0.07%
+145,189
New +$4.77M
ATAI icon
97
AtaiBeckley Inc
ATAI
$2.65B
$3.23M 0.07%
218,730
-132,257
-38% -$2.15M
KZR
98
DELISTED
Kezar Life Sciences
KZR
$2.25M 0.05%
+26,000
New +$1.72M
AKLI
99
DELISTED
Akili Inc
AKLI
$1.99M 0.04%
200,000
– –
DNAB
100
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.98M 0.04%
200,000
– –
2 3
4
5 6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2021 Portfolio in Review

As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $783M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 95% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.

  • Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
  • Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
  • Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
  • Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
  • Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
  • Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.